Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for sight-threatening diseases, and Otsuka Pharmaceutical Co., Ltd., (Otsuka) a Japan-based, “big venture” pharmaceutical company, today announced results from a recently completed phase IIa study of emixustat hydrochloride in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).
Help employers find you! Check out all the jobs and post your resume.
